Pulmonx Corp

NASDAQ:LUNGUnited States

Pulmonx Corporation is a commercial-stage medical technology company. The Company provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. Its solutions, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform (StratX Platform), is designed to treat severe emphysema patients. The StratX Platform is a cloud-based quantitative CT analysis service that offers physicians with a report that is designed for its solution, which includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation and has been validated in multiple randomized controlled clinical trials.

Contact Information

Headquarters

700 Chesapeake DrREDWOOD CITY, CA, United States 94063

Phone

650-934-2600

Fax

302-655-5049

Executives

Independent Chairman of Board

Dana Mead

President, Chief Executive Officer, Director

Steven Williamson

Chief Financial Officer and Principal Financial and Chief Accounting Officer

Mehul Joshi

General Counsel

David Lehman

Chief Commercial Officer

Geoffrey Rose